** Shares of cancer therapy developer Oncternal Therapeutics
hit record low, last down 59.32% at $1.69
** Co says it will discontinue its trials studying its experimental cancer therapies ONCT-534 and ONCT-808 and will explore strategic alternatives
** In early stage trial, ONCT-534, which is being studied in patients with metastatic castration resistant cancer, did not show clinically meaningful improvements of disease
** There was one death related to complications of shock at the highest dose tested with ONCT-808
** While the strategic exploration is ongoing, co will discontinue all product development activities and will take other steps to reduce costs, including a workforce reduction to preserve cash resources
** Stock down 85% YTD
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。